RxDoctor Payments Data

Carol Wade

Nurse Practitioner · Baltimore, MDNPI 1639118011

Payments from drug & device makers

$1,637in general payments, 2019–2025

Across 31 payments — averaging $52.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$548
  • Cvrx, Inc.$188
  • Bayer$165
  • Boehringer Ingelheim$156
  • Scpharmaceuticals Inc.$129
  • Johnson & Johnson$118
  • plus $335 from 6 others

What the payments were for

  • Food & beverage$1,637100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,637 in reported general payments places this provider in the 85th percentile of 1,562 nurse practitioner providers in Maryland.

See all nurse practitioner providers in Maryland

Medicare billing

Part B allowed, 2024
$30,542
Medicare patients
103
Services billed
543

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan63$57,807
JardianceEmpagliflozin52$45,475
EliquisApixaban35$25,895
FarxigaDapagliflozin Propanediol25$15,586
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$8,252
VerquvoVericiguat12$7,549
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine13$4,097
Bumetanide14$864
Spironolactone94$823
Metoprolol Succinate42$636
Torsemide34$590
Atorvastatin Calcium38$416
Losartan Potassium58$392
Potassium Chloride19$284
Tamsulosin Hcl28$247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$106$57,80763 claims
Boehringer IngelheimJardiance$156$45,47552 claims
PfizerEliquis$89$25,89535 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,562 nurse practitioner providers in Maryland.

Other nurse practitioner in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →